KR20070091198A - Taurine synthesis, production and utility as a medicine - Google Patents

Taurine synthesis, production and utility as a medicine Download PDF

Info

Publication number
KR20070091198A
KR20070091198A KR1020077016443A KR20077016443A KR20070091198A KR 20070091198 A KR20070091198 A KR 20070091198A KR 1020077016443 A KR1020077016443 A KR 1020077016443A KR 20077016443 A KR20077016443 A KR 20077016443A KR 20070091198 A KR20070091198 A KR 20070091198A
Authority
KR
South Korea
Prior art keywords
effective
concentrations
taurine
prevention
control
Prior art date
Application number
KR1020077016443A
Other languages
Korean (ko)
Inventor
마그드 아메드 코트브 압달라
Original Assignee
마그드 아메드 코트브 압달라
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 마그드 아메드 코트브 압달라 filed Critical 마그드 아메드 코트브 압달라
Publication of KR20070091198A publication Critical patent/KR20070091198A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/57Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C323/58Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups with amino groups bound to the carbon skeleton
    • C07C323/59Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups with amino groups bound to the carbon skeleton with acylated amino groups bound to the carbon skeleton
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/145Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01Sulfonic acids
    • C07C309/02Sulfonic acids having sulfo groups bound to acyclic carbon atoms
    • C07C309/03Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C309/13Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing nitrogen atoms, not being part of nitro or nitroso groups, bound to the carbon skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01Sulfonic acids
    • C07C309/02Sulfonic acids having sulfo groups bound to acyclic carbon atoms
    • C07C309/03Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C309/13Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing nitrogen atoms, not being part of nitro or nitroso groups, bound to the carbon skeleton
    • C07C309/14Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing nitrogen atoms, not being part of nitro or nitroso groups, bound to the carbon skeleton containing amino groups bound to the carbon skeleton

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The quantitatively most important pathway for the excretion of cholesterol in mammals is the formation of bile salts (the conjugate bases of bile acids). The major bile salts are synthesized and secreted by as glycine or taurine conjugates. Taurine (2 aminoethyl sulphonic acid) is naturally produced by the liver cells and central nervous system cells, it is neuroprotective and is a cholesterol lowering agent with virtually no recorded side effects.

Description

타우린 합성, 생산 및 의약으로서의 용도{TAURINE SYNTHESIS, PRODUCTION AND UTILITY AS A MEDICINE}TAURINE SYNTHESIS, PRODUCTION AND UTILITY AS A MEDICINE}

의약medicine

포유류의 콜레스테롤의 배출을 위한 정량적으로 가장 중요한 경로는 담즙 염(담즙산의 짝염기)의 형성이다. 주요 담즙 염은 글리신 또는 타우린 접합체(conjugate)로서 합성되고, 분비된다. The quantitatively most important route for the release of cholesterol in mammals is the formation of bile salts (covalent bases of bile acids). The major bile salts are synthesized and secreted as glycine or taurine conjugates.

발명의 개시Disclosure of the Invention

타우린은 시스테인의 분해 생성물이다. 타우린(2-아미노에틸 설폰산)은 담즙의 성분이다. 이는 콜린산과 결합하여 타우로콜린산을 형성한다. 콜린산은 콜레스테롤의 신진대사의 산물이다. 콜린산의 형성은 몇몇의 수산화 및 산화 반응을 포함하는 경로를 포함한다. 모든 수용성 비타민이 이 반응에 참여한다.Taurine is a degradation product of cysteine. Taurine (2-aminoethyl sulfonic acid) is a component of bile. It combines with cholic acid to form taurocholine acid. Choline acid is the product of cholesterol metabolism. Formation of choline acid involves a pathway that involves several hydroxylation and oxidation reactions. All water soluble vitamins participate in this reaction.

타우린은 콜레스테롤 수치를 낮추고, 그리고 이 작용은 수용성 비타민의 존재에 의해 강화된다. Taurine lowers cholesterol levels, and this action is enhanced by the presence of water-soluble vitamins.

타우린은 고콜레스테롤혈증, 고트리글리세리드혈증 및 쓸개즙정체 또는 콩팥증후군 등과 같은 모든 지질 관련한 장애를 낮추는 데 효과적이고, 또한 가족성 또는 특발성 또는 후천성 지질 장애의 임의의 유형에 효과적이다. 타우린은 심장보호성이다. Taurine is effective in lowering all lipid related disorders such as hypercholesterolemia, hypertriglyceridemia and cholestasis or kidney disease, and is also effective in any type of familial or idiopathic or acquired lipid disorder. Taurine is cardioprotective.

타우린은 또한 담석 처치(dissolution)에 효과적이다.Taurine is also effective in the treatment of gallstones.

타우린은 안전하고, 그리고 고 콜레스테롤, 저 밀도 지단백 또는 초저밀도 지단백을 정상화하는 데 효과적이다.Taurine is safe and effective at normalizing high cholesterol, low density lipoproteins, or ultra low density lipoproteins.

타우린은 또한 혈액 삼투압의 변화에 대항하는 뇌 세포의 안정화 및 세로토닌의 엔돌핀으로의 전환에 필수적이다. 이는 우울증, 편두통, 두통, 알츠하이머 병 및 정신질환 및 신경계질환에 효과적이다. Taurine is also essential for stabilizing brain cells against changes in blood osmotic pressure and for converting serotonin into endorphins. It is effective in depression, migraines, headaches, Alzheimer's disease and mental and nervous system diseases.

신규 아이디어New ideas

제어하는 것: 지질, 지단백, 콜레스테롤의 혈액 수준 및 고콜레스테롤혈증과 관련되는 질병, 정신질환 및 신경계질환 및 담석 처치, 이하가 단독으로 또는 조합된 것이 효과적이다:Controlling: Treatment of diseases related to lipids, lipoproteins, blood levels of cholesterol and hypercholesterolemia, mental and neurological diseases and gallstones, alone or in combination, are effective:

a. 타우린a. Taurine

b. 시스테인 및/또는 아세틸 시스테인b. Cysteine and / or acetyl cysteine

c. 모든 수용성 비타민c. All water soluble vitamins

요구되는 특허의 자세한 설명Detailed description of the required patent

a. 에틸 알코올의 설폰화 후 C2에서 치환 반응 또는 재조합 DNA 기술에 의한 2-아미노에틸 설폰산을 생성 또는 임의의 가능한 방법으로서 모든 공지된 방법에 의해, 또는 장에 기생하는 세균성 식물상(flora)의 이용을 촉진하는 프로바이오틱을 이용하여 사전에 간에서 형성된 타우로콜린산 및 타우로케노데옥시콜린산 등으로부터 타우린을 회수함으로써 제조되는 타우린. a. Production of 2-aminoethyl sulfonic acid by substitution reaction or recombinant DNA technology at C2 after sulfonation of ethyl alcohol or by any known method or by the use of bacterial flora that is parasitic in the intestine A taurine produced by recovering taurine from taurocholine acid, taurokenodeoxycholic acid, etc. previously formed in the liver using a promoting probiotic.

b. 모든 공지된 방법에 의해 제조되는 아세틸 시스테인.b. Acetyl cysteine prepared by all known methods.

c. 모든 공지된 방법에 의해 제조되는 수용성 비타민.c. Water soluble vitamins prepared by all known methods.

여기에서:From here:

ⅰ. "a" 또는 "b" 또는 "c"로서, 또는 "a+b" 또는 "a+c" 또는 "b+c" 또는 "a+b+c"로서 주어진다면, 모든 "a", "b" 및 "c"는 효과적이다. Iii. If given as "a" or "b" or "c", or as "a + b" or "a + c" or "b + c" or "a + b + c", all "a", "b "And" c "are effective.

ⅱ. 경구 또는 비경구 또는 국부성 제제로 제공될 때, "a" 또는 "b" 또는 "c"로서, 또는 "a+b" 또는 "a+c" 또는 "b+c" 또는 "a+b+c"로서 주어진다면, 모든 "a" 또는 "b" 및 "c"는 효과적이다.Ii. When provided in oral or parenteral or topical formulations, as "a" or "b" or "c", or "a + b" or "a + c" or "b + c" or "a + b + If given as "c", all "a" or "b" and "c" are effective.

ⅲ. "a" 또는 "b" 또는 "c", 또는 "a+b" 또는 "a+c" 또는 "b+c" 또는 "a+b+c"의 모든 그리고 임의의 조성물 및 임의의 그리고 모든 농도가 효과적이다.Iii. all and any composition and any and all concentrations of “a” or “b” or “c”, or “a + b” or “a + c” or “b + c” or “a + b + c” Is effective.

ⅳ. 이용되는 타우린은 이의 산 형태 또는 산 염 또는 알칼리 염 또는 임의의 이의 화합물 또는 형태로 나타난다.Iii. The taurine used is represented in its acid form or in acid or alkali salts or in any compound or form thereof.

ⅴ. 임의의 그리고 모든 농도 및 조합의 "a" 또는 "b" 또는 "c", 또는 "a+b" 또는 "a+c" 또는 "b+c" 또는 "a+b+c"는 아테롬성 경화증 및 심장질환의 예방 및 제어에 효과적이다.Iii. Any and all concentrations and combinations of "a" or "b" or "c", or "a + b" or "a + c" or "b + c" or "a + b + c" means atherosclerosis and Effective for the prevention and control of heart disease.

ⅵ. 임의의 그리고 모든 농도 및 조합의 "a" 또는 "b" 또는 "c", 또는 "a+b" 또는 "a+c" 또는 "b+c" 또는 "a+b+c"는 모든 고콜레스테롤혈증, 고트리글리세리드혈증 및 모든 그리고 임의의 지질 및 지단백 장애의 예방 및 제어에 효과적이다.Iii. Any and all concentrations and combinations of “a” or “b” or “c”, or “a + b” or “a + c” or “b + c” or “a + b + c” are all high cholesterol It is effective in the prevention and control of hypertension, hypertriglyceridemia and all and any lipid and lipoprotein disorders.

ⅶ. 임의의 그리고 모든 농도 및 조합의 "a" 또는 "b" 또는 "c", 또는 "a+b" 또는 "a+c" 또는 "b+c" 또는 "a+b+c"는 임의의 병인론의 쓸개즙정체의 예방 및 제어에 효과적이다.Iii. Any and all concentrations and combinations of "a" or "b" or "c", or "a + b" or "a + c" or "b + c" or "a + b + c" is any etiology It is effective in the prevention and control of cholestasis of bile.

ⅷ. 임의의 그리고 모든 농도 및 조합의 "a" 또는 "b" 또는 "c", 또는 "a+b" 또는 "a+c" 또는 "b+c" 또는 "a+b+c"는 간의 지방증 및 임의의 병인론의 지방간염 장애의 예방 및 제어에 효과적이다.Iii. Any and all concentrations and combinations of “a” or “b” or “c”, or “a + b” or “a + c” or “b + c” or “a + b + c” is a fatty steatosis and It is effective in the prevention and control of hepatitis disorders of any etiology.

ⅸ. 임의의 그리고 모든 농도 및 조합의 "a" 또는 "b" 또는 "c", 또는 "a+b" 또는 "a+c" 또는 "b+c" 또는 "a+b+c"는 담석 질환의 예방, 처치 및 제어에 효과적이다.Iii. Any and all concentrations and combinations of "a" or "b" or "c", or "a + b" or "a + c" or "b + c" or "a + b + c" may be used for gallstone disease Effective for prevention, treatment and control.

ⅹ. 임의의 그리고 모든 농도 및 조합의 "a" 또는 "b" 또는 "c", 또는 "a+b" 또는 "a+c" 또는 "b+c" 또는 "a+b+c"는 모든 정신질환 및 모든 신경계질환의 예방 및 제어에 효과적이다.Iii. Any and all concentrations and combinations of “a” or “b” or “c”, or “a + b” or “a + c” or “b + c” or “a + b + c” are all mental disorders And effective in the prevention and control of all neurological diseases.

Claims (10)

"a" 또는 "b" 또는 "c"로서, 또는 "a+b" 또는 "a+c" 또는 "b+c" 또는 "a+b+c"로서 주어진다면, 모든 "a", "b" 및 "c"는 효과적이다. If given as "a" or "b" or "c", or as "a + b" or "a + c" or "b + c" or "a + b + c", all "a", "b "And" c "are effective. 단, a는 에틸 알코올의 설폰화 후 C2에서 치환 반응 또는 재조합 DNA 기술에 의한 2-아미노에틸 설폰산을 생성 또는 임의의 가능한 방법으로서 모든 공지된 방법에 의해, 또는 장에 기생하는 세균성 식물상(flora)의 이용을 촉진하는 프로바이오틱을 이용하여 사전에 간에서 형성된 타우로콜린산 및 타우로케노데옥시콜린산 등으로부터 타우린을 회수함으로써 제조되는 타우린이고,Provided that a is a bacterial flora that is parasitic to the intestine by any known method or by any known method of producing 2-aminoethyl sulfonic acid by substitution reaction or recombinant DNA technology at C2 after sulfonation of ethyl alcohol. Taurine prepared by recovering taurine from taurocholinic acid, taurokenodeoxycholic acid, etc. previously formed in the liver using a probiotic that promotes the use of b는 모든 공지된 방법에 의해 제조되는 아세틸 시스테인이고,b is acetyl cysteine prepared by all known methods, c는 모든 공지된 방법에 의해 제조되는 수용성 비타민이다.c is a water soluble vitamin prepared by all known methods. 경구 또는 비경구 또는 국부성 제제로 제공될 때, "a" 또는 "b" 또는 "c"로서, 또는 "a+b" 또는 "a+c" 또는 "b+c" 또는 "a+b+c"로서 주어진다면, 모든 "a" 또는 "b" 및 "c"는 효과적이다. 단, a, b, c는 제1항에서 정의한 바와 같다.When provided in oral or parenteral or topical formulations, as "a" or "b" or "c", or "a + b" or "a + c" or "b + c" or "a + b + If given as "c", all "a" or "b" and "c" are effective. Provided that a, b, and c are as defined in claim 1. 모든 그리고 임의의 조성물 및 임의의 그리고 모든 농도가 효과적인 "a" 또는 "b" 또는 "c", 또는 "a+b" 또는 "a+c" 또는 "b+c" 또는 "a+b+c". 단, a, b, c는 제1항에서 정의한 바와 같다."A" or "b" or "c", or "a + b" or "a + c" or "b + c" or "a + b + c, in which all and any compositions and any and all concentrations are effective ". Provided that a, b, and c are as defined in claim 1. 타우린의 산 형태 또는 산 염 또는 알칼리 염 또는 임의의 이의 화합물 또는 형태 또는 형상으로 나타나는 이용되는 타우린. 단, a, b, c는 제1항에서 정의한 바와 같다.Taurine used in the acid form or acid salt or alkali salt of taurine or in any compound or form or form thereof. Provided that a, b, and c are as defined in claim 1. 아테롬성 경화증 및 심장질환의 예방 및 제어에 효과적인 임의의 그리고 모든 농도 및 조합의 "a" 또는 "b" 또는 "c", 또는 "a+b" 또는 "a+c" 또는 "b+c" 또는 "a+b+c". 단, a, b, c는 제1항에서 정의한 바와 같다."A" or "b" or "c", or "a + b" or "a + c" or "b + c" in any and all concentrations and combinations effective for the prevention and control of atherosclerosis and heart disease "a + b + c". Provided that a, b, and c are as defined in claim 1. 모든 고콜레스테롤혈증, 고트리글리세리드혈증 및 모든 그리고 임의의 지질 및 지단백 장애의 예방 및 제어에 효과적인 임의의 그리고 모든 농도 및 조합의 "a" 또는 "b" 또는 "c", 또는 "a+b" 또는 "a+c" 또는 "b+c" 또는 "a+b+c". 단, a, b, c는 제1항에서 정의한 바와 같다."A" or "b" or "c", or "a + b" or any and all concentrations and combinations effective for the prevention and control of all hypercholesterolemia, hypertriglyceridemia and all and any lipid and lipoprotein disorders "a + c" or "b + c" or "a + b + c". Provided that a, b, and c are as defined in claim 1. 임의의 병인론의 쓸개즙정체의 예방 및 제어에 효과적인 임의의 그리고 모든 농도 및 조합의 "a" 또는 "b" 또는 "c", 또는 "a+b" 또는 "a+c" 또는 "b+c" 또는 "a+b+c". 단, a, b, c는 제1항에서 정의한 바와 같다."A" or "b" or "c", or "a + b" or "a + c" or "b + c" in any and all concentrations and combinations effective for the prevention and control of the cholestasis of any etiology Or "a + b + c". Provided that a, b, and c are as defined in claim 1. 간의 지방증 및 임의의 병인론의 지방간염 장애의 예방 및 제어에 효과적인 임의의 그리고 모든 농도 및 조합의 "a" 또는 "b" 또는 "c", 또는 "a+b" 또는 "a+c" 또는 "b+c" 또는 "a+b+c". 단, a, b, c는 제1항에서 정의한 바와 같다."A" or "b" or "c", or "a + b" or "a + c" or "of any and all concentrations and combinations effective for the prevention and control of hepatic steatosis and hepatic hepatitis disorder of any etiology b + c "or" a + b + c ". Provided that a, b, and c are as defined in claim 1. 담석 질환의 예방, 처치 및 제어에 효과적인 임의의 그리고 모든 농도 및 조합의 "a" 또는 "b" 또는 "c", 또는 "a+b" 또는 "a+c" 또는 "b+c" 또는 "a+b+c". 단, a, b, c는 제1항에서 정의한 바와 같다."A" or "b" or "c", or "a + b" or "a + c" or "b + c" or "of any and all concentrations and combinations effective for the prevention, treatment and control of gallstone disease a + b + c ". Provided that a, b, and c are as defined in claim 1. 모든 정신질환 및 모든 신경계질환의 예방 및 제어에 효과적인 임의의 그리고 모든 농도 및 조합의 "a" 또는 "b" 또는 "c", 또는 "a+b" 또는 "a+c" 또는 "b+c" 또는 "a+b+c". 단, a, b, c는 제1항에서 정의한 바와 같다."A" or "b" or "c", or "a + b" or "a + c" or "b + c, in any and all concentrations and combinations effective for the prevention and control of all mental and all neurological diseases "Or" a + b + c ". Provided that a, b, and c are as defined in claim 1.
KR1020077016443A 2005-01-05 2005-12-31 Taurine synthesis, production and utility as a medicine KR20070091198A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EG2005010013 2005-01-05
EG2005010013 2005-01-05

Publications (1)

Publication Number Publication Date
KR20070091198A true KR20070091198A (en) 2007-09-07

Family

ID=36647837

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020077016443A KR20070091198A (en) 2005-01-05 2005-12-31 Taurine synthesis, production and utility as a medicine

Country Status (15)

Country Link
EP (1) EP1844006A2 (en)
JP (1) JP2008526789A (en)
KR (1) KR20070091198A (en)
CN (1) CN101146767A (en)
AP (1) AP2007004084A0 (en)
AU (1) AU2005324199A1 (en)
BR (1) BRPI0519606A2 (en)
CA (1) CA2593563A1 (en)
EA (1) EA200701434A1 (en)
IL (1) IL184221A0 (en)
MA (1) MA29238B1 (en)
MX (1) MX2007008196A (en)
NO (1) NO20074937A (en)
TN (1) TNSN07226A1 (en)
WO (1) WO2006072259A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101932238B (en) 2007-11-30 2015-04-08 加利福尼亚大学董事会 Methods of treating non-alcoholic steatohepatitis (nash) using cysteamine products
CN103382170B (en) * 2012-10-25 2015-04-08 潜江永安药业股份有限公司 Preparation method for taurine
CN106728405A (en) * 2016-11-15 2017-05-31 陈思文 A kind of taurine and water soluble tea polyphenol compound and preparation method and application

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58140017A (en) * 1981-12-22 1983-08-19 Junichi Azuma Remedy for cardiac insufficiency
JPH08208464A (en) * 1994-12-02 1996-08-13 Taisho Pharmaceut Co Ltd Agent for treatment and prevention of hyperlipemia
US6184227B1 (en) * 1995-07-21 2001-02-06 Savvipharm Inc. Salts of aminoimidazole carboxamide useful in the prevention and treatment of liver diseases
SE9601395D0 (en) * 1996-04-12 1996-04-12 Dieter Haeussinger New therapeutic treatment 1
GB9722361D0 (en) * 1997-10-24 1997-12-17 Pharma Nord Uk Ltd Pharmaceutical formulation for treating liver disorders
NZ527924A (en) * 1999-01-29 2005-01-28 Mars Uk Ltd Antioxidant compositions and methods for companion animals
AU8003800A (en) * 1999-10-08 2001-04-23 Joyce Corinne Bechthold Methods and compositions for treating neurobehavioral disorders
CN1340502A (en) * 2000-06-30 2002-03-20 张永春 Process for preparing taurine zinc
CN1268733C (en) * 2004-07-20 2006-08-09 刘辉 Taurine functional beer and its producing process

Also Published As

Publication number Publication date
AU2005324199A1 (en) 2006-07-13
WO2006072259A2 (en) 2006-07-13
MA29238B1 (en) 2008-02-01
TNSN07226A1 (en) 2008-11-21
CN101146767A (en) 2008-03-19
WO2006072259A3 (en) 2007-10-04
JP2008526789A (en) 2008-07-24
MX2007008196A (en) 2008-02-22
AP2007004084A0 (en) 2007-08-31
IL184221A0 (en) 2008-12-29
NO20074937A (en) 2007-09-28
EA200701434A1 (en) 2008-10-30
EP1844006A2 (en) 2007-10-17
BRPI0519606A2 (en) 2009-02-25
CA2593563A1 (en) 2006-07-13

Similar Documents

Publication Publication Date Title
ES2256472T3 (en) NATURAL PHENOLIC PRODUCTS AND DERIVED FROM THEM FOR THE PROTECTION AGAINST NEURODEGENERATIVE DISEASES.
CN101307088B (en) Method for preparing cholic acid conjugates
US9301931B2 (en) Methods of use for 2,5-dihydroxybenzene sulfonic acid compounds for the treatment of cancer, rosacea and psoriasis
TW589186B (en) Ascorbyl-phosphoryl-cholesterol
EP0703954B1 (en) Polyphenol derivative compositions and preparation thereof
JPH11504914A (en) 1,3-propanediol derivatives as biologically active compounds
CN104395273A (en) Prodrugs of vitamine K
ITFI20070224A1 (en) NEW S-ACYL SURFACES OF GLUTATHY, THEIR SYNTHESIS AND USE IN THE TREATMENT OF PATHOLOGIES RELATED TO THE CELL OXIDATIVE STRESS
FR2873376A1 (en) NOVEL SELENO-HYDROXYACIDS AND DERIVATIVES, NUTRITION APPLICATIONS, COSMETICS AND PHARMACY
KR20090112631A (en) Novel lipid compounds
KR20070091198A (en) Taurine synthesis, production and utility as a medicine
CA2633225C (en) Novel polyunsaturated compounds, method for preparing same and compositions containing same
BRPI0611316B1 (en) processes for the preparation, separation or purification of phosphatidylserine
FR2704753A1 (en) Use of derivatives of 4-thio resorcin or 4-thio 1-3-dihydroxybenzene, in cosmetic or dermopharmaceutical compositions with depigmenting action.
JP7073384B2 (en) Compounds and usage
JP4226324B2 (en) Carboxylic acid type lipid
WO2011030727A1 (en) External preparation containing pantethine phosphate ester
JP2008504231A (en) Oxidized dibenzo-alpha-pyrone chromoprotein
JP2011241164A5 (en)
AU766045B2 (en) Phospholipid derivatives of non-steroidal anti-inflammatory drugs
JP2021508732A (en) Glucosamine derivatives to prevent or treat joint disorders
CN107759553A (en) New flavonoids and application thereof
JP4861753B2 (en) Skin external composition
CN112888419A (en) Compositions and methods for treating and preventing Leber&#39;s hereditary optic neuropathy
WO2021187314A1 (en) Mitochondrial dysfunction improving agent

Legal Events

Date Code Title Description
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid